Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic …
Results: Short term UDCA administration stimulated BA synthesis by reducing circulating fibroblast growth factor 19 and farnesoid X receptor (FXR) activation, resulting in cholesterol …
顶刊综述丨NAT REV MICROBIOL (IF:78): 胆汁酸和肠道微生物群: 代 …
2023年3月4日 · udca和lca都是fxr激动剂，可以通过fxr-fgf15途径减轻代谢综合征。 当用LCA和UDCA治疗时，肥胖小鼠的胆固醇、血浆甘油三酯和血浆脂肪酸水平降低，这是由于FXR …
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects ...
Here we show that short term UDCA administration, by replacing hydrophobic FXR-agonistic BAs and thereby reducing FXR anti-lipogenic effects, impacts on lipid conversion processes via …
硬核综述 | 贾伟/郑晓皎教授团队揭秘胆汁酸在全身代谢和免疫稳态 …
2023年10月9日 · 贾伟教授团队此前研究表明，回肠中猪胆酸类（HCAs）可以同时激活TGR5和抑制FXR，促进肠道GLP-1的合成和分泌，降低血糖【6】。 BAs在调节甘油三酯（TG）和胆固 …
FXR inhibition may protect from SARS-CoV-2 infection by ... - Nature
2022年12月5日 · We show that the UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused …
Combinatorial therapy with BAR502 and UDCA resets FXR and
2023年1月28日 · In the present study we have compared the effects of BAR502, a dual FXR/GPBAR1 ligand) alone or in combination with ursodeoxycholic acid (UDCA) in a model of …
Nature新进展：熊去氧胆酸（UDCA）等FXR 抑制可通过降低血管 …
2023年7月26日 · 研究人员发现使用非处方植物类固醇z-guggulsterone（ZGG）和非专利药物熊去氧胆酸（UDCA）可以减少FXR信号传导并下调人肺，胆管细胞和肠道类器官以及小鼠和仓鼠 …
β-Sitosterol protects against lithocholic acid-induced …
3 天之前 · FXR activation is involved in the hepatoprotective effect of SIT in vivo and in vitro. ... Although UDCA is authorized for the cure of cholestasis, about 40 % of individuals with PBC …
Therapeutic implication of oxidative stress-induced growth
6 天之前 · Obeticholic acid (OCA), a ligand for farnesoid-X-receptor (FXR), and ursodeoxycholic acid (UDCA), an agonist for G-protein coupled bile acid receptor 1 (GPBAR1), have been used …
A Placebo-Controlled Phase 2 Trial of E6011, Anti-Human …
3 天之前 · For those with an incomplete response to UDCA, about 20-30% of patients with PBC, obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, was officially approved in 2016, …